European Journal of Clinical Pharmacology

, Volume 31, Issue 1, pp 63–68 | Cite as

Pharmacokinetics of trimazosin and its effects on blood pressure, renal function and proteinuria during short-term therapy of patients with impaired renal function and hypertension

  • C. K. van Kalken
  • J. van der Meulen
  • P. L. Oe
  • R. Vriesendorp
  • A. J. M. Donker


The kinetics and short-term (10 weeks) effects of trimazosin, an alpha1-adrenoreceptor antagonist, on renal function and blood pressure in patients with moderate chronic renal insufficiency and hypertension, have been studied for the first time. Eight patients in whom the blood pressure was not normalized with a diuretic alone underwent pharmacokinetic studies and assessment of the renal function during a 10-week period of trimazosin therapy. Trimazosin significantly lowered blood pressure (recumbent and upright) without significantly altering renal function. Renal vascular resistance was decreased by 14%. Fractional sodium excretion, proteinuria and laboratory serum tests remained unchanged. Neither body weight nor pulse rate were affected. Moderate renal insufficiency did not modify the pharmacokinetics of the drug. Thus, trimazosin, as second-step antihypertensive agent, appeared to be safe and effective in patients with moderate renal insufficiency and hypertension, without exerting favourable or adverse renal effects during short-term therapy.

Key words

trimazosin proteinuria chronic renal insufficiency hypertension glomerular filtration rate renal vascular resistance pharmacokinetics 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Reid JL, Meredith PA, Eliott HL (1983) Pharmacokinetics and pharmacodynamics of trimazosin in man. Am Heart J 106: 1222–1227Google Scholar
  2. 2.
    Koshy MC, Mickley D, Boorgoignie J, Blaufox MD (1977) Physiologic evaluation of a new antihypertensive agent: Prazosin HCL. Circulation 55: 533–537Google Scholar
  3. 3.
    Cambridge D, Davey MJ, Massingham R (1977) Prazosin, a selective antagonist of postsynaptic alpha1-adrenoreceptors. Br J Pharmacol 59: 514–515Google Scholar
  4. 4.
    Chrysant SG (1983) Autonomic, systemic and renal haemodynamic actions of trimazosin in hypertensive patients. Am Heart J 106: 1243–1250Google Scholar
  5. 5.
    Constantine JW, Hess HJ (1981) The cardiovascular effects of trimazosin. Eur J Pharmacol 74: 227–238Google Scholar
  6. 6.
    Chrysant SG, Miller RF, Brown JL, Danisa K (1981) Long-term haemodynamic and metabolic effects of trimazosin in essential hypertension. Clin Pharmacol Ther 30: 600–612Google Scholar
  7. 7.
    DeGuia D, Mendlowitz M, Russo C, Vlachakis N, Antram S (1973) The effect of trimazosin in essential hypertension. Curr Ther Res 15: 339–348Google Scholar
  8. 8.
    Vlachakis N, Mendlowitz M, Deguzman D (1975) Treatment of essential hypertension with trimazosin, a new vasodilator agent. Curr Ther Res 17: 564–569Google Scholar
  9. 9.
    Pool PE, Seagren SC, Salel AF (1983) Clinical haemodynamic profile of trimazosin in hypertension. Am Heart J 106: 1237–1242Google Scholar
  10. 10.
    Aronow WS, Tobis J, Hughes D, Siegel J, Easthope J (1977) Comparison of trimazosin and methyldopa in hypertension. Clin Pharmacol Ther 22: 425–429Google Scholar
  11. 11.
    Taylor CR, Leader JP, Singleton W, Munster EW, Falkner FC, O'Neil JA (1983) Profile of trimazosin: An effective and safe antihypertensive agent. Am Heart J 106: 1269–1283Google Scholar
  12. 12.
    Chrysant SG, Luu TM, Danisa K, Kem DC, Manion CV (1980) Systemic and renal haemodynamic effects of trimazosin: a new vasodilator. J Cardiovasc Pharmacol 2: 205–214Google Scholar
  13. 13.
    Hughes MA, Meredith PA, Eliott HL (1986) The determination of trimazosin and its metabolite (CP 23445) in whole blood by high performance liquid chromatography using fluorescence detection. J Chromatogr (in press)Google Scholar
  14. 14.
    Donker AJM, van der Hem GK, Sluiter WJ, Beekhuis H (1977) A radioisothope method for simultaneous determination of the glomerular filtration rate and the effective renal plasma flow. Neth J Med 20: 97–102Google Scholar
  15. 15.
    Gomez DM (1951) Evaluations of renal resistance with special reference to changes in essential hypertension. J Clin Invest 30: 1143–1155Google Scholar
  16. 16.
    Starke K, Docherty JR (1980) Recent developments in alpha-adrenoreceptor research. J Cardiovasc Pharmacol 2: 269–286Google Scholar
  17. 17.
    O'Connor DT, Preston RA, Sasso EH (1979) Renal perfusion changes during treatment of essential hypertension: prazosin versus propranolol. J Cardiovasc Pharmacol 1: 38–42Google Scholar

Copyright information

© Springer-Verlag 1986

Authors and Affiliations

  • C. K. van Kalken
    • 1
  • J. van der Meulen
    • 1
  • P. L. Oe
    • 1
  • R. Vriesendorp
    • 1
  • A. J. M. Donker
    • 1
  1. 1.Department of MedicineFree University HospitalAmsterdamThe Netherlands

Personalised recommendations